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H19 is a maternally expressed non-
coding RNA located at chromosome 
11p15.5 near the reciprocally imprinted 
insulin-like growth factor 2 (IGF2) gene. 
Though the function of H19 is unknown, 
it is transcribed during embryonic 
development after which transcription is 
absent in all but a few tissues including 
cardiac muscle, breast, ovary, uterus, 
and placenta. Over the past fifteen 
years, however, high H19 expression 
has been seen in a number of human 
cancers. Recently, the 2.6kb H19 
transcript was shown to be the pre-
miRNA of miR-675 whose target mRNA 
is the tumor suppressor RB1. 
 
 We have carried out real-time PCR 
assays for H19, miR-675, and RB1 
transcription in seven endometrial 
cancer cell lines and a panel of 27 
primary endometrial tumors. Results 
showed that H19 and miR-675 
expression is highly correlated (r = 0.84) 
and that miR-675 and RB1 expression 
levels are negatively correlated (r = -
0.52). Among the primary tumors, miR-
675 expression is unchanged in 
endometrioid tumors compared to 
benign endometrium (-1.3 fold) but is 
increased in carcinosarcomas (2.7 fold) 
and is highest in serous tumors (7.2 
fold). 
  
Linking H19, miR-675 and RB1 
expression with serous tumors of the 
endometrium suggests that RB1 
suppression may be a differentiating 
event in serous tumorigenesis. 
 
 
